Magnesium sulphate versus diazepam in the management of eclampsia: a randomized controlled trial.
This randomized controlled trial compared the use of magnesium sulphate with diazepam as anticonvulsant in 51 eclamptic women. The use of magnesium sulphate was associated with less serious morbidity (in terms of recurrence of convulsions, cardiopulmonary problems, disseminated intravascular coagulopathy, and acute renal failure) but the difference was not statistically significant (relative risk 0.6; 95% CI 0.3 to 1.2). The one maternal death occurred in the magnesium sulphate group. Convulsions recurred in five (21%) women in the magnesium sulphate group and seven (26%) women in the diazepam group. Urine output poor enough to prompt diuretic stimulation was less frequent in the magnesium sulphate group than in the diazepam group (RR 0.3; 95% CI 0.1 to 0.9). Significantly fewer infants born in the magnesium sulphate group had low Apgar scores (less than 7 at 1 min) compared with those in the diazepam group (RR 0.6; 95% CI 0.4 to 0.9). There were two early neonatal deaths in the magnesium sulphate group, and three stillbirths in the diazepam group. This study suggests that magnesium sulphate has advantages over diazepam for the mother and the infant in the treatment of eclampsia, but the trial is small and should be replicated on a larger scale.
Crowther
C
C
Department of Obstetrics and Gynaecology, University of Zimbabwe, Harare.
D001034:Apgar Score; D003975:Diazepam / Q000008:administration & dosage / Q000627:therapeutic use*; D004461:Eclampsia / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D007273:Injections, Intramuscular; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000627:therapeutic use*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence
D008278:Magnesium Sulfate; D003975:Diazepam